Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts,
are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non …

Chromosomal instability (CIN) drives cancer cell evolution, metastasis and therapy
resistance, and is associated with poor prognosis. CIN leads to micronuclei that release …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Cancer is driven by multiple types of genetic alterations, which range in size from point
mutations to whole-chromosome gains and losses, known as aneuploidy. Chromosome …

A variety of targeted anticancer agents have been successfully introduced into clinical
practice, largely reflecting their ability to inhibit specific molecular alterations that are …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

PI3Ks are a family of lipid kinases that phosphorylate intracellular inositol lipids to regulate
signalling and intracellular vesicular traffic. Mammals have eight isoforms of PI3K, divided …

Chemotherapy is the main treatment used for cancer patients failing surgery. Doxorubicin
(DOX) is a well-known chemotherapeutic agent capable of suppressing proliferation in …